A previous clinical trial found that tamoxifen, taken for five years, reduced the risk of developing invasive breast cancer by about 50% in post-menopausal women who were at increased risk of getting the disease.
Another trial found that five years of raloxifene reduces breast cancer risk in such women by about 38%.
Under the new plans, high risk post-menopausal women could be offered the drugs for a period of five years unless they have a history of thromboembolic disease or endometrial cancer.
More top news
UK defence secretary says so-called Islamic State group will only be defeated by force.
Sheriff's deputies were called to the scene in LA County after residents reported hearing muffled crying.
Further one in eight expect to be aged between 71 and 80 years when they finally stop work, according to survey.